Literature DB >> 21448012

Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action.

Steven J Katz1, Anthony S Russell.   

Abstract

PURPOSE OF REVIEW: Whereas antimalarials have been in use to treat rheumatic disease for over 50 years, their exact mechanism of action remains unclear. Over the past decade, new theories have been proposed in this regard both for rheumatic disease, as well as related conditions. RECENT
FINDINGS: Whereas the classical explanation was an impairment of phago/lysosomal function, antimalarials also appear to have an impact through inhibition of intracellular toll-like receptors (TLRs), particularly TLR9. This may mediate its effect on lupus, rheumatoid arthritis, as well as ancillary conditions including diabetes and hyperlipidemia. The potential role for antimalarials in antiphospholipid syndrome also appears clearer, with an effect proposed through Annexin5 binding.
SUMMARY: Despite their established clinical utility, the mode of action for antimalarials remains uncertain despite recent advances and still requires further investigation. By better understanding how antimalarials function, their optimal use in the clinical setting can be ensured.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448012     DOI: 10.1097/BOR.0b013e32834456bf

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  31 in total

1.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

Review 2.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 3.  Can rheumatoid arthritis be prevented?

Authors:  Kevin D Deane
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-10-02       Impact factor: 4.098

Review 4.  Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.

Authors:  Eben I Lichtman; Simon M Helfgott; Martin A Kriegel
Journal:  Clin Immunol       Date:  2012-04-06       Impact factor: 3.969

5.  Macroautophagy is deregulated in murine and human lupus T lymphocytes.

Authors:  Frédéric Gros; Johan Arnold; Nicolas Page; Marion Décossas; Anne-Sophie Korganow; Thierry Martin; Sylviane Muller
Journal:  Autophagy       Date:  2012-04-23       Impact factor: 16.016

6.  Cell wall perturbation sensitizes fungi to the antimalarial drug chloroquine.

Authors:  Farida Islahudin; Combiz Khozoie; Steven Bates; Kang-Nee Ting; Richard J Pleass; Simon V Avery
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

7.  Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients.

Authors:  Juliana Cruz da Silva; Henrique Ataide Mariz; Laurindo Ferreira da Rocha; Priscilla Stela Santana de Oliveira; Andrea Tavares Dantas; Angela Luzia Branco Pinto Duarte; Ivan da Rocha Pitta; Suely Lins Galdino; Maira Galdino da Rocha Pitta
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

Review 8.  B-cell selection and the development of autoantibodies.

Authors:  Natalia V Giltiay; Craig P Chappell; Edward A Clark
Journal:  Arthritis Res Ther       Date:  2012-11-02       Impact factor: 5.156

Review 9.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

Review 10.  Neurology of rheumatologic disorders.

Authors:  Amre Nouh; Olimpia Carbunar; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 6.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.